<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Emanuele Bosi - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/emanuele-bosi/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/emanuele-bosi/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Mon, 08 Jul 2019 13:28:24 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>Emanuele Bosi - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/emanuele-bosi/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Medtronic ha annunciato i risultati dello studio SMILE</title>
		<link>https://www.newpharmaitaly.it/medtronic-ha-annunciato-i-risultati-dello-studio-smile/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Mon, 08 Jul 2019 13:28:24 +0000</pubDate>
				<category><![CDATA[Innovazione]]></category>
		<category><![CDATA[diabete tipo 1]]></category>
		<category><![CDATA[Emanuele Bosi]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[Ospedale San Raffaele]]></category>
		<category><![CDATA[Robert Vigersky]]></category>
		<guid isPermaLink="false">https://www.newpharmaitaly.it/?p=3737</guid>

					<description><![CDATA[<p>Diabete di tipo 1: nuovo studio Medtronic dimostra la sicurezza e l&#8217;efficacia del MiniMed™ 640G, sistema che riduce l’insorgenza di episodi ipoglicemici Medtronic plc (NYSE: MDT), leader mondiale in tecnologie, servizi e soluzioni mediche, ha annunciato la pubblicazione su The Lancet Diabetes &#38; Endocrinology dello Studio SMILE &#8211; Study of MiniMed 640G Insulin Pump with SmartGuardTM [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/medtronic-ha-annunciato-i-risultati-dello-studio-smile/">Medtronic ha annunciato i risultati dello studio SMILE</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
